Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmacabtagene Autoleucel Combo for PCNSL
NCT07198464Not yet recruiting
- Sponsor
- Zhengzhou University
- Start
- Oct 2025
- Primary completion
- Oct 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Open-label, single-arm trial of relmacabtagene autoleucel in primary central nervous system lymphoma (PCNSL), sponsored by Zhengzhou University. Primary endpoints: Progression-Free Survival at 60 months and Overall Response Rate at 3 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07198464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198464.